Bortezomib inhibits cell proliferation in prostate cancer

Zheng,Ren‑Ping; Wang,Wei; Wei,Chuan‑Dong

doi:10.3892/etm.2015.2617

September-2015 Volume 10 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 10 Issue 3

Full Size Image

Article

Bortezomib inhibits cell proliferation in prostate cancer

Authors:
- Ren‑Ping Zheng
- Wei Wang
- Chuan‑Dong Wei
View Affiliations / Copyright

Affiliations: Department of Urology, First People's Hospital of Jiujiang, Jiujiang, Jiangxi 332000, P.R. China, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Clinical Laboratory, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, P.R. China
Pages: 1219-1223
|
Published online on: July 3, 2015

https://doi.org/10.3892/etm.2015.2617
Expand metrics +

Abstract

Despite the improvement in chemotherapeutic agents, the outcome of patients with prostate cancer remains poor. It is therefore imperative that new anticancer drugs are explored. The aim of the present study was to investigate the inhibitory effect of bortezomib on DU145 prostate cancer cells. The DU145 cell proliferation rate was detected via MTT assay prior to and following exposure to various concentrations of bortezomib, and the level of cell apoptosis and the cell cycle distribution were tested using flow cytometry. In addition, western blotting was used to measure the expression of Bcl‑2‑interacting killer (Bik) and active‑caspase‑3. The results showed that bortezomib inhibited the proliferation of DU145 cells in a time‑ and dose‑dependent manner. Following treatment with 1.6 µmol/l bortezomib, the DU145 cells showed marked nuclear condensation, chromatin condensation and fragmentation. Analysis of the cell cycle revealed a significantly increased percentage of cells in the G0/G1 phase and a decreased percentage in the S and G2/M phases. The rate of DU145 cell apoptosis was significantly higher in the bortezomib group than that in the control group, and this was accompanied by an enhanced expression of Bik and active‑caspase‑3. It can be concluded that bortezomib inhibits the proliferation of DU145 cells by inducing apoptosis. The underlying mechanism may involve the upregulation of Bik and active‑caspase‑3 expression.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Sankila R, Ferlay J and Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 38:99–166. 2002. View Article : Google Scholar : PubMed/NCBI
4	Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood. 108:2165–2172. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ryan DP, O'Neil BH, Supko JG, et al: A Phase I study of Bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 107:2688–2697. 2006. View Article : Google Scholar : PubMed/NCBI
6	Voorhees PM and Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 46:189–213. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zhu H, Zhang L, Dong F, et al: Bik/NBK accumulation correlates with apoptosis-induction by Bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene. 24:4993–4999. 2005. View Article : Google Scholar : PubMed/NCBI
8	Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, et al: Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol. 19:565–574. 2012. View Article : Google Scholar : PubMed/NCBI
9	Morris MJ, Kelly WK, Slovin S, et al: A phase II trial of Bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol. 178:2378–2383. 2007. View Article : Google Scholar : PubMed/NCBI
10	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ulmer JB, Wahren B and Liu MA: DNA vaccines: Recent technological and clinical advances. Discov Med. 6:109–112. 2006.PubMed/NCBI
12	Nasu Y and Kumon H: Prostate cancer gene therapy. Nihon Rinsho. 63:485–490. 2005.(In Japanese). PubMed/NCBI
13	Chen Z, Hagler J, Palombella VJ, et al: Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 9:1586–1597. 1995. View Article : Google Scholar : PubMed/NCBI
14	Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 5:417–421. 2004. View Article : Google Scholar : PubMed/NCBI
15	Fan XM, Wong BC, Wang WP, et al: Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer. 93:481–488. 2001. View Article : Google Scholar : PubMed/NCBI
16	Papandreou CN and Logothetis CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64:5036–5043. 2004. View Article : Google Scholar : PubMed/NCBI
17	Huang DC and Strasser A: BH3-only proteins - essential initiators of apoptotic cell death. Cell. 103:839–842. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kumar S: Caspase function in programmed cell death. Cell Death Differ. 14:32–43. 2007. View Article : Google Scholar : PubMed/NCBI
19	de Oca J, Azuara D, Sanchez-Santos R, et al: Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. Int J Colorectal Dis. 23:21–27. 2008. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Bortezomib inhibits cell proliferation in prostate cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles